ArticleFrontiers in pharmacology2025

Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China.

Xiangcheng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.